Showing 3691-3700 of 4063 results for "".
- Clearside Biomedical Announces FDA Acceptance of Investigational NDA for CLS-AX Administered in Suprachoroidal Spacehttps://modernod.com/news/clearside-biomedical-announces-fda-acceptance-of-investigational-nda-for-cls-ax-administered-in-suprachoroidal-space/2478140/Clearside Biomedical announced that the FDA has accepted its investigational new drug (IND) application for CLS-AX (axitinib injectable suspension), enabling initiation of a phase 1/2a clinical trial of CLS-AX in wet age-related macular degeneration (AMD) patients by the end of 20
- American College of Surgeons Strongly Opposes Proposed Medicare Physician Fee Schedulehttps://modernod.com/news/american-college-of-surgeons-strongly-opposes-proposed-medicare-physician-fee-schedule/2478117/The American College of Surgeons (ACS) stated that it strongly opposes the Medicare Physician Fee Schedule proposed rule released by the Centers for Medicare & Medicaid Services (CMS) for 2021, which hurts our health care system and surgical care at the expense of patients. Although the propo
- Proposed Medicare Physician Fee Schedule Rule Jeopardizes Patient Care, Argues the Surgical Care Coalitionhttps://modernod.com/news/proposed-medicare-physician-fee-schedule-rule-jeopardizes-patient-care-argues-the-surgical-care-coalition/2478115/The Medicare Physician Fee Schedule proposed rule released by the Centers for Medicare & Medicaid Services (CMS) for 2021 jeopardizes patient care, specifically surgical care, according to a Surgical Care Coalition news release. While the proposed rule takes steps to increase access to care t
- Oxurion Appoints Grace Chang, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/oxurion-appoints-grace-chang-md-phd-as-chief-medical-officer/2478109/Oxurion NV announced the appointment of Grace Chang, MD, PhD, as the company’s Chief Medical Officer, effective August 1, 2020. Dr. Chang is a board-certified ophthalmologist and practicing vitreoretinal surgeon with deep expertise in ophthalmic drug research and development. She will be r
- Kubota Vision Demonstrates 3D Imaging Capabilities Using AI on PBOShttps://modernod.com/news/kubota-vision-demonstrates-3d-imaging-capabilities-using-ai-on-pbos/2478095/Kubota Vision announced that the company demonstrated 3D imaging capabilities using artificial intelligence (AI) on its Patient Based Ophthalmology Suite (PBOS) in-home optical coherence tomography (OCT) device.1 Kubota Vision completed a successful clinical study in October 201
- Hanita Lenses Announces Launch of Intensity IOLhttps://modernod.com/news/hanita-lenses-announces-launch-of-intensity-iol/2478082/After 3 years of development, Israel-based Hanita Lenses announced the launch of the Intensity IOL. The Intensity is a presbyopia-correcting IOL that has been developed by employing a proprietary iterative algorithm—called the Dynamic Light Utilization (DLU) technology—for better light eff
- Updated National Report Outlining the Current State of Children’s Vision and Eye Healthhttps://modernod.com/news/updated-national-report-outlining-the-current-state-of-childrens-vision-and-eye-health/2478059/As part of August’s Children’s Eye Health and Safety Month, and as a follow-up to its 2016 publication, The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has released an updated version of the report titled “Children’s Vision and Eye Health: A Snapshot of Curr
- National Vision Announces Special Cash Bonus to Front-Line Associates and Doctorshttps://modernod.com/news/national-vision-announces-special-cash-bonus-to-front-line-associates-and-doctors/2478032/National Vision Holdings announced plans to grant a special cash bonus to front-line associates and doctors. A one-time $250 bonus will be given to all patient-facing and customer-facing associates and the company’s network of doctors in recognition of their hard work and dedication toward
- CorNeat Vision’s Synthetic Cornea Approved for First-in-Human Implantationhttps://modernod.com/news/corneat-visions-synthetic-cornea-approved-for-first-in-human-implantation/2478011/The CorNeat KPro, which says it is developing the first synthetic cornea that bio-integrates with the eye wall, received approval to begin a clinical trial at Beilinson Hospital, Israel. The clinical trial, approved by Israel’s
- Arctic Vision Announces $32 Million in Series A to Expand and Develop Ophthalmology Pipelinehttps://modernod.com/news/arctic-vision-announces-32-million-in-series-a-to-expand-and-develop-ophthalmology-pipeline/2478009/Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, announced its $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focu